Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.

Nelson JC, Rahman Z, Laubmeier KK, Eudicone JM, McQuade RD, Berman RM, Marcus RN, Baker RA, Sheehan JJ.

CNS Spectr. 2014 Dec;19(6):528-34. doi: 10.1017/S109285291300103X. Epub 2014 Mar 18.

2.

Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.

Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, Marcus RN, Berman RM, Baker RA.

Int Clin Psychopharmacol. 2012 May;27(3):125-33. doi: 10.1097/YIC.0b013e3283502791.

PMID:
22466058
3.

Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.

Steffens DC, Nelson JC, Eudicone JM, Andersson C, Yang H, Tran QV, Forbes RA, Carlson BX, Berman RM.

Int J Geriatr Psychiatry. 2011 Jun;26(6):564-72. doi: 10.1002/gps.2564. Epub 2010 Sep 9.

4.

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.

CNS Spectr. 2009 Apr;14(4):197-206.

PMID:
19407731
5.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A.

J Clin Psychiatry. 2007 Jun;68(6):843-53.

PMID:
17592907
6.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.

Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM.

J Clin Psychopharmacol. 2008 Apr;28(2):156-65. doi: 10.1097/JCP.0b013e31816774f9.

PMID:
18344725
7.

Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.

Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, Tran QV, Pikalov A, Carlson BX, Marcus RN, Berman RM.

J Clin Psychiatry. 2008 Dec;69(12):1928-36. Epub 2008 Dec 2.

PMID:
19192475
8.

Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.

Stewart TD, Hatch A, Largay K, Sheehan JJ, Marler SV, Berman RM, Nelson JC.

J Affect Disord. 2014 Jun;162:20-5. doi: 10.1016/j.jad.2014.03.017. Epub 2014 Mar 24.

9.

Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.

Casey DE, Laubmeier KK, Eudicone JM, Marcus R, Berman RM, Rahman Z, Sheehan J.

Int J Clin Pract. 2014 Nov;68(11):1301-8. doi: 10.1111/ijcp.12480. Epub 2014 Sep 6.

PMID:
25196314
10.

Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).

Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T; ADMIRE Study Group.

J Affect Disord. 2013 Dec;151(3):899-905. doi: 10.1016/j.jad.2013.07.035. Epub 2013 Aug 28.

11.

Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.

Wisniewski SR, Chen CC, Kim E, Kan HJ, Guo Z, Carlson BX, Tran QV, Pikalov A.

Pharmacoepidemiol Drug Saf. 2009 Oct;18(10):965-72. doi: 10.1002/pds.1805.

PMID:
19662630
12.

Adjunctive aripiprazole for depression: predictive value of early assessment.

Muzina DJ, Chambers JS, Camacho TA, Eudicone JM, Forbes RA, Berman RM, Baker RA.

Am J Manag Care. 2011 Dec;17(12):793-801.

13.

A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).

Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M.

Psychother Psychosom. 2012;81(2):87-97. doi: 10.1159/000332050. Epub 2012 Jan 25. Erratum in: Psychother Psychosom. 2012;81(4):261.

PMID:
22286203
14.

Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.

Weisler RH, Khan A, Trivedi MH, Yang H, Eudicone JM, Pikalov A, Tran QV, Berman RM, Carlson BX.

J Clin Psychiatry. 2011 Apr;72(4):548-55. doi: 10.4088/JCP.09m05495gre. Epub 2010 Aug 24.

PMID:
20816039
15.
16.

Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.

Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E.

Int Clin Psychopharmacol. 2009 May;24(3):133-8. doi: 10.1097/YIC.0b013e3283277614.

PMID:
19318972
17.

Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.

Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M.

J Clin Psychiatry. 2012 Mar;73(3):353-7. doi: 10.4088/JCP.10m06541. Epub 2011 Sep 20.

PMID:
21939613
18.

Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies.

Nelson JC, Mankoski R, Baker RA, Carlson BX, Eudicone JM, Pikalov A, Tran QV, Berman RM.

J Affect Disord. 2010 Jan;120(1-3):133-40. doi: 10.1016/j.jad.2009.06.026.

PMID:
19656577
19.

Aripiprazole: in major depressive disorder.

Weber J, Lyseng-Williamson KA, Scott LJ.

CNS Drugs. 2008;22(10):807-13. Review.

PMID:
18788833
20.

Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.

Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H.

J Clin Psychiatry. 2015 Sep;76(9):1224-31. doi: 10.4088/JCP.14m09688.

Supplemental Content

Support Center